查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080173

僵直性脊椎炎（AS）：新型療法、未滿足的需求和TPP洞察報告，2026年

Ankylosing Spondylitis (AS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到 2035 年，德國僵直性脊椎炎市場規模將從約 12 億美元成長到 21 億美元。
  • 以下因素正在推動市場成長：
  • 生物製藥和標靶治療的應用日益廣泛
  • 人們對這種疾病的認知不斷提高，早期診斷也取得了進展。
  • 市場規模的擴大是由治療週期長和高品質治療方案的出現所推動的。
  • 未來的成長取決於下一代免疫調節療法和個人化治療策略。

僵直性脊椎炎(AS) 的新療法及對 TPP 的深入研究

Thelansis 發布的「僵直性脊椎炎(AS)：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026 年」對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

僵直性脊椎炎（AS）概述

僵直性脊椎炎是一種慢性免疫介導的脊椎關節病，與HLA-B27基因進行性相關，其特徵是由於肌腱附著點炎、骶髂關節炎以及嚴重的TNF和IL-17軸功能障礙導致的進行性椎體融合。此病表現為逐漸加重的發炎性腰痛和持續性晨僵，活動後症狀可緩解。非肌肉骨骼觀察包括急性前葡萄膜炎、廣泛性尋常型斑塊型乾癬和無症狀性發炎性腸道疾病。診斷是基於臨床症狀、急性期反應物升高以及骨盆腔MRI證實的骶髂關節發炎的綜合評估。疾病嚴重程度和結構損傷程度採用檢驗的ASDAS和BASDAI指數來量化。儘管口服非類固醇抗發炎藥（NSAIDs）仍然是治療症狀的一線藥物，但最新更新的臨床指南建議採用針對難治性或侵蝕性疾病的「達標治療」策略，使用先進的標靶治療。第一線生物製藥包括IL-17A和IL-17F雙重抑制劑，例如比美珠單抗（bimekizumab），以及新一代口服JAK抑制劑，例如Upadacitinib）。重要的是，治療流程中優先考慮患者的合併症。對於活動性葡萄膜炎或嚴重結構性腸道疾病患者，強烈建議使用單株TNF抑制劑；而在腸道疾病急性發作期間，應嚴格避免使用IL-17抑制劑。除了這些先進的生物製藥外，指導性物理治療和系統性的脊椎活動範圍監測對於抑制長期骨性強直、最大限度降低心血管合併症風險以及最大限度改善患者的身體功能至關重要。

主要亮點

  • 根據預測，德國僵直性脊椎炎患者人數將從 2025 年的約 202,963 人增加到 2035 年的 216,565 人。
  • 僵直性脊椎炎是一種慢性發炎性疾病，會導致脊椎進行性損傷和活動能力下降。
  • 早期診斷和治療對於減緩結構性病變進展和維持身體機能至關重要。
  • 生物製藥和標靶治療已顯著改善了疾病的治療效果。
  • 持續性疾病活動和診斷延遲仍然是主要的臨床挑戰。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗現況分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 特徵和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 主要未滿足需求得到滿足的程度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Shenzhen Huishan Biotechnology Co., Ltd.
  • Lynk Pharmaceuticals Co., Ltd.
  • Sunshine Guojian Pharmaceutical（Shanghai）Co., Ltd.
  • SPH-BIOCAD（HK）Limited
  • UCB Biopharma SRL
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Akeso
  • Janssen Research &Development, LLC
  • Biocad
  • Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
  • Johnson &Johnson Private Limited
  • AbbVie
  • XBiotech, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Ankylosing Spondylitis (AS) Emerging Therapy and TPP Insights

Thelansis's "Ankylosing Spondylitis (AS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Ankylosing Spondylitis (AS) Overview

Ankylosing Spondylitis is a chronic, immune-mediated spondyloarthropathy strongly associated with the HLA-B27 gene, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by severe TNF and IL-17 axis dysregulation. It manifests as insidious, inflammatory back pain and persistent morning stiffness that improves with physical activity. Extramusculoskeletal signs include acute anterior uveitis, extensive plaque psoriasis, and subclinical inflammatory bowel disease. Diagnosis combines clinical presentation, elevated acute-phase reactants, and sacroiliac joint inflammation caught on pelvic MRI. Severity and structural damage are quantified using validated ASDAS and BASDAI metrics. While oral NSAIDs remain the first-line symptomatic cornerstone, newly updated clinical guidelines enforce a specialized, treat-to-target strategy using advanced targeted therapies for refractory or erosive disease. Frontline biologics feature dual IL-17A and IL-17F inhibitors like bimekizumab and next-generation oral JAK inhibitors like upadacitinib. Importantly, management algorithms prioritize patient-specific comorbidities: for patients with concurrent active uveitis or severe structural bowel disease, monoclonal TNF inhibitors are heavily prioritized, whereas IL-17 blockers are strictly avoided in active intestinal flares. Supervised physical therapy and structured spinal mobility monitoring are mandated alongside these advanced biologics to limit long-term bony ankylosis, minimize elevated cardiovascular comorbidity risks, and maximize physical functional capacity.

Key Highlights

  • In Germany, the diagnosed ankylosing spondylitis patient pool is projected to increase from approximately 202,963 in 2025 to 216,565 by 2035.
  • Ankylosing spondylitis remains a chronic inflammatory disease causing progressive spinal damage and reduced mobility.
  • Early diagnosis and treatment are essential to slowing structural progression and preserving physical function.
  • Biologic therapies and targeted treatments have significantly improved disease outcomes.
  • Persistent disease activity and delayed diagnosis continue to represent key clinical challenges.

Market Overview

  • The Germany ankylosing spondylitis market is projected to grow from approximately $1.2 BN to $2.1 BN by 2035.
  • Market growth is supported by:
  • Increasing adoption of biologics and targeted therapies
  • Growing awareness and earlier disease diagnosis
  • Market value growth is driven by long-term treatment duration and premium therapeutic options.
  • Future growth will depend on next-generation immunomodulatory therapies and personalized treatment strategies.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Shenzhen Huishan Biotechnology Co., Ltd.
  • Lynk Pharmaceuticals Co., Ltd.
  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
  • SPH-BIOCAD (HK) Limited
  • UCB Biopharma SRL
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • Akeso
  • Janssen Research & Development, LLC
  • Biocad
  • Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
  • Johnson & Johnson Private Limited
  • AbbVie
  • XBiotech, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)